Medicare procedure market data by CPT code & state

Market snapshot

Nationwide CY2024

Medicare Part B FFS · CY2024 · as published by CMS

J9025 Injection, azacitidine, 1 mg HCPCS · Chemotherapy treatment

Classification Treatment › Chemotherapy › Chemotherapeutic Agent (CMS RBCS)

First observed 2013 — start of our 12-year window; the code predates it

National scale 5.34M services · est. ▲ 0.2% YoY · 2,749 FFS beneficiaries (CY2024, all-Medicare estimate) — 2.70M observed fee-for-service services

Medicare paid $1.6M · est. · $0.29 avg / service, national — $793K observed FFS

CMS descriptor · RBCS classification · Medicare Part B physician/supplier claims, 12-year window

Billing groups

Named groups billing this code

Named-group all-Medicare svcs · est.

4,811,299

Scaled from 2,439,700 observed FFS services.

FFS of Medicare

49%

Payer-mix frame

Services · year over year

Services YoY

+0.2%

All-Medicare est. · observed FFS -3.9%

Volume, not care. A shrinking fee-for-service denominator is not a shrinking market.

Estimated all-Medicare volume estimate

FFS + estimated MA

~4,811,299 services

2,439,700 observed fee-for-service (51%) · ~2,371,599 estimated Medicare Advantage.

Scaled from the observed floor by each state’s fee-for-service share (FFS share as of 2024) — scaled estimate — assumes MA utilization mirrors FFS; not an observation. How we scale

Top states — J9025 (CY2024)

FL 1,385,663 TX 667,401 VA 560,741 IL 437,031 CA 355,328

Est. all-Medicare services by billing state (scaled estimate — assumes MA utilization mirrors FFS); open a bar for that state's ranked market.

Billed → allowed → paid

Named-group submitted charges

$22.6M

Named-group allowed amount

$910K

Named-group Medicare payments

$1.4M · est.

— $718K observed FFS

Avg charge / svc

Avg allowed / svc

Avg payment / svc

Totals are named-group (attributable) sums. Allowed is Medicare’s fee-schedule recognized price — what CMS recognizes, before the 80% Medicare pays.

Average charge per group

$1–3

$3–5

$5–7

$7–9

$9–11

$11–13

$13–15

$15+

$1 34 groups · avg submitted charge / service $24

Market analyticsPlatform Methods →

Search a single state to see that market's full analytics — each panel renders gated on the free tier.

See it in full: nuclear heart imaging (78452) in Arizona is open as a live example — every paid panel, on real data.

View the live example →

Data year: CY2024 CY2023 CY2022 CY2021 CY2020

Physician groups ranked by J9025 services, highest first, CY2024
#	Physician group locked column	City locked column	St locked column	Specialty locked column	Providers locked column	J9025 svcs	Submitted charges locked column	Avg charge locked column	Medicare $ locked column	Share of state* locked column	Phone
1	FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC	FORT MYERS	FL	HEMATOLOGY/ONCOLOGY	437	403,849	$1,615,396	$4	premium	66.5%	(239) 561-9622
2	TEXAS ONCOLOGY PA	DALLAS	TX	PHYSICIAN ASSISTANT	995	300,305	$3,903,965	$13	premium	96.6%	—
3	VIRGINIA ONCOLOGY ASSOCIATES	NORFOLK	VA	PHYSICIAN ASSISTANT	123	298,300	$5,834,282	$20	premium	86.0%	—
4	ONCOLOGY-HEMATOLOGY ASSOCIATES OF CENTRAL ILLINOIS P C	PEORIA	IL	NURSE PRACTITIONER	62	219,300	$1,897,400	$9	premium	87.7%	(309) 243-3000
5	SCRIPPS HEALTH	LA JOLLA	CA	PHYSICIAN ASSISTANT	1431	146,291	$405,400	$3	premium	83.5%	(858) 455-9100

That's the top 5 of 34 groups. The platform ranks the whole market — code baskets, benchmarks, and the full ranked list. the full ranking is part of the market analytics platform — built, not launched yet. Notify me at launch →

*Share of the state's disclosed Medicare-FFS services for the primary code, counted once per clinician. "St" is the state the volume was billed from: a group appears in each state where its clinicians bill Medicare, with that state's volume and share ("City" is the group's registered location). Group figures sum clinicians affiliated with exactly one group; clinicians in several groups are listed in each group's drill-down but not volume-attributed to any single group, so shares reflect attributable volume. See Methods.

Comparing against an all-payer estimate?

These are exact counts from Medicare fee-for-service claims — roughly a third to half of most procedure markets, depending on payer mix — and the observed foundation every market figure here builds on. Market totals anchor on a labeled all-Medicare estimate scaled from that foundation, with the observed count disclosed beside it — Medicare only, never all-payer. Modeled all-payer databases project every payer statistically and typically run higher. Same market, different denominator. How the numbers reconcile →